<?xml version="1.0" encoding="UTF-8"?>
<p>Coronavirus Disease 2019 (COVID‐19) convalescent plasma (CP) was widely proposed as a potential therapy for COVID‐19 in the United States (US) during the initial months of viral spread within the country.
 <xref rid="trf16015-bib-0001" ref-type="ref">
  <sup>1</sup>
 </xref>, 
 <xref rid="trf16015-bib-0002" ref-type="ref">
  <sup>2</sup>
 </xref> Prior to that, it was used to treat a limited number of COVID‐19 patients in China, with suggestion of possible efficacy and no clear adverse effects.
 <xref rid="trf16015-bib-0003" ref-type="ref">
  <sup>3</sup>
 </xref> Furthermore, CP has been utilized during epidemics for nearly 100 years.
 <xref rid="trf16015-bib-0004" ref-type="ref">
  <sup>4</sup>
 </xref> A number of hospital‐based and national blood collection centers, including the NorthShore University HealthSystem Blood Bank, rapidly began convalescent plasma collection programs as an Institutional Review Board (IRB) approved clinical research program.
</p>
